CA2285567A1 - Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2 - Google Patents

Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2 Download PDF

Info

Publication number
CA2285567A1
CA2285567A1 CA002285567A CA2285567A CA2285567A1 CA 2285567 A1 CA2285567 A1 CA 2285567A1 CA 002285567 A CA002285567 A CA 002285567A CA 2285567 A CA2285567 A CA 2285567A CA 2285567 A1 CA2285567 A1 CA 2285567A1
Authority
CA
Canada
Prior art keywords
phenyl
furanone
methylsulfonyl
compound
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002285567A
Other languages
English (en)
Inventor
Serge Leger
Erich Grimm
Petpiboon Prasit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709356.1A external-priority patent/GB9709356D0/en
Application filed by Individual filed Critical Individual
Publication of CA2285567A1 publication Critical patent/CA2285567A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un nouveau composé de formule (I) et un procédé de traitement des maladies induites par COX-2 consistant à administrer à un patient une quantité non toxique thérapeutiquement efficace d'un composé de formule (I). L'invention concerne aussi certaines compositions pharmaceutiques destinées au traitement de maladies induites par COX-2 comprenant des composés de formule (I).
CA002285567A 1997-04-02 1998-03-31 Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2 Abandoned CA2285567A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4253597P 1997-04-02 1997-04-02
US60/042,535 1997-04-02
GB9709356.1 1997-05-07
GBGB9709356.1A GB9709356D0 (en) 1997-05-07 1997-05-07 Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
PCT/CA1998/000302 WO1998043966A1 (fr) 1997-04-02 1998-03-31 Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2

Publications (1)

Publication Number Publication Date
CA2285567A1 true CA2285567A1 (fr) 1998-10-08

Family

ID=26311502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002285567A Abandoned CA2285567A1 (fr) 1997-04-02 1998-03-31 Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2

Country Status (5)

Country Link
EP (1) EP0971910A1 (fr)
JP (1) JP2001518087A (fr)
AU (1) AU6818298A (fr)
CA (1) CA2285567A1 (fr)
WO (1) WO1998043966A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
CN100488500C (zh) 2000-07-20 2009-05-20 劳拉斯有限公司 Cox-2抑制剂预防免疫缺陷的用途
AU2002306150B2 (en) 2001-06-13 2008-02-14 Magnachem International Laboratories, Inc. Lactone formulations and method of use
JP4869597B2 (ja) 2002-11-05 2012-02-08 マグナケム インターナショナル ラボラトリーズ， インコーポレイテッド 合成ラクトン処方物ならびに使用方法
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
WO2005102315A1 (fr) 2004-04-23 2005-11-03 Magnachem International Laboratories, Inc. Formulations de lactone synthetique pour maitrise la douleur
EP2350645A2 (fr) 2008-10-24 2011-08-03 Magnachem International Laboratories, Inc. Procédé d'analyse de composés interagissant de manière sélective avec rad9
CA3209491A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire
WO2023150719A1 (fr) * 2022-02-03 2023-08-10 Purdue Research Foundation Alpha-méthylène et alpha-aminométhyl lactones et lactames pour le traitement d'une infection à clostridium difficile (cdi)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2747123B1 (fr) * 1996-04-04 1998-06-26 Union Pharma Scient Appl Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique

Also Published As

Publication number Publication date
JP2001518087A (ja) 2001-10-09
AU6818298A (en) 1998-10-22
EP0971910A1 (fr) 2000-01-19
WO1998043966A1 (fr) 1998-10-08

Similar Documents

Publication Publication Date Title
EP0912518B1 (fr) Pyridines substituees en tant qu'inhibiteurs selectifs de la cyclo-oxygenase-2
US5922742A (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
CA2234642C (fr) 3,4-diaryle-2-hydroxy-2,5-dihydrofurans utilises comme promedicaments pour inhibiteurs de cox-2
CA2283399C (fr) Pyridazinones utilises comme inhibiteurs de cyclo-oxygenase-2
EP1012142B1 (fr) Pyridines 2,3,5-trisubstituees utilisees comme inhibiteurs de la cyclo-oxygenase 2
US6046217A (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6133292A (en) Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6465509B2 (en) Pyrones as inhibitors of cyclooxygenase-2
CA2285567A1 (fr) Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2
CA2244134C (fr) Stilbenes de diphenyle utilises en tant que promedicaments d'inhibiteurs de cox-2
AU2001268881A1 (en) Pyrones as inhibitors of cyclooxygenase-2
CA2283100A1 (fr) (methylsufonyl)phenyl-2-(5h)-furanones a liaison oxygene, utilises comme inhibiteurs de cyclo-oxygenase-2
AU741790B2 (en) Diaryl-5-alkyl-5-methyl-2(5H)-furanones as selective cyclooxygenase-2 inhibitors
US6004960A (en) Pyridazinones as inhibitors of cyclooxygenase-2
US6004950A (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
EP1015431B1 (fr) 2-aminopyridines utilisees comme inhibiteurs de la cyclo-oxygenase 2
CA2252401C (fr) Pyridinyl-2-cyclopenten-1-ones utilisees comme inhibiteurs de cyclooxygenase selectifs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead